MNKD

MannKind has executed a genuine commercial turnaround: revenue has compounded from $75M (FY2021) to $349M (FY2025, +22.2% YoY), and the business swung from deep losses to positive net income in FY2024. The model is also de-risking from a single product — it now spans Afrezza (inhaled insulin), the October 2025 scPharma-acquired Furoscix (subcutaneous loop diuretic), V-Go, and a high-quality recurring royalty/supply stream on United Therapeutics' Tyvaso DPI, plus an expanding UT collaboration (MNKD-1501). Operating income of $38.8M and positive operating cash flow of $18.3M show the core is self-funding, not a cash-burning clinical shell.

But the FY2025 numbers carry clear warning signs tied to the scPharma deal. Net income collapsed -78.7% to $5.86M and diluted EPS fell to $0.02, operating cash flow dropped -57.1%, long-term debt exploded +883.7% to $355M, and total liabilities ($843M) now exceed total assets, leaving stockholders' equity at -$51.0M against a -$3.20B accumulated deficit. The acquisition more than doubled the asset base (+101.1%) but levered the balance sheet, and cash of $74.9M is thin relative to $355M of debt — management itself only claims it can meet 'near-term' liquidity needs and flags its ability to service debt as a risk.